Crinetics Pharmaceuticals Inc. (CRNX) has a key regulatory event coming up next month, which has the potential to significantly impact its stock price.
The company's lead asset is Paltusotine, the first once-daily, oral, selectively targeted somatostatin receptor type 2 agonist in development for the proposed treatment of people with acromegaly.
Acromegaly is caused by a benign pituitary tumor that secretes excess growth hormone (GH). This overproduction of GH leads to somatic overgrowth, causing enlarged hands, feet, distinctive facial changes, multiple comorbidities, and even premature mortality.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.